Formed by OrbiMed, the Silverstein Foundation for Parkinson's with GBA, and a Columbia University neurologist, Prevail (PRVL) is applying gene therapies to genetic
subsets of neurodegenerative diseases, including Parkinson's Disease (PD). It’s using the same technology deployed by Novartis in their recently approved super expensive ($2 million) therapy Zolgensma for spinal muscular atrophy for infants.
Here are three other things you need to know about Prevail.
To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.Start a Free Trial of IPO Pro
The article Prevail IPO Aims to Conquer Parkinson’s originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StoryPRVL
Latest IPOs Videos
- Chinese SPAC Yunhong International prices upsized US IPO at $10
- Oncology biotech Revolution Medicines raises IPO range to $16 to $17 with market cap set to exceed $1 billion
- Cannabis SPAC Greenrose Acquisition prices $150 million IPO at $10
- Canadian trucking company TFI International files for a $199 million US IPO